Toxicities

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or[...]

By afschroeder • October 7, 2025